About the webinar

The landscape of cardiovascular disease (CVD) research is rapidly evolving with the integration of next generation proteomics with multiomics capabilities. In this webinar, Sarantis will explore how next-generation proteomic studies enable deeper mechanistic insights, support precision patient stratification, and patient monitoring and treatment in cardiovascular disease. Olink’s proximity extension assay technology (PEA™) further advances these trials as a non-invasive approach requiring only limited sample input, which is especially critical in clinical settings for monitoring patients and advancing treatment decisions in clinical practice.

Drawing on large-scale studies, including fine-mapped blood eQTL and pQTL analyses and proteomic profiling from the EMPEROR heart-failure trials (Zannad et al. 2022), we will highlight how protein-level regulation provides a more direct window into tissue biology. The session will demonstrate how proteomics can validate target engagement, identify early biomarkers of disease progression, and uncover pathways modulated by therapeutic intervention.

Sarantis willl also discuss emerging evidence around whether protein biomarkers can serve as a non-invasive method to enhance patient selection, drug-response prediction, and may ultimately ease timelines for successful drug approval.

About Sarantis Chlamydas

Dr. Sarantis Chlamydas is Senior Scientific Lead for MultiOmics Strategy, Innovation & Alliances at Olink Proteomics, part of Thermo Fisher Scientific. With over 15 years of experience in proteomics, epigenetics, and gene regulation, he drives the integration of MultiOmics technologies for biomarker discovery, precision medicine and drug development.

He is successfully leading international collaborations with pharmaceutical companies, academic institutions, and clinical consortia, with a strong focus on translational research and precision health.  Dr. Chlamydas holds honorary academic positions and actively contributes to education and scientific advancement. He also serves on the steering committees of major consortia dedicated to biomarker discovery and the clinical implementation of MultiOmics solutions.